- Champignon Brands Appoints Mr. Jim Bailey to the Company’s Special Advisory Committee
- Mr. Bailey is the Former President of Red Bull Canada
- Mr. Bailey Will Lead Champignon’s Marketing, Distribution and Commercialization of the Company’s Novo Formulations-Branded Novel Delivery Systems for the Pharmaceutical, Nutraceutical and Psychedelic Medicine Industries
Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FRA: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine has further bolstered its pharmaceutical, nutraceutical and CPG marketing/distribution competencies via the appointment of the former President of Red Bull Canada, Mr. Jim Bailey, to its Special Advisory Committee.
Mr. Bailey previously served as the Global Chief Marketing Officer for Merrell Outdoors, overseeing both product and consumer marketing with annual revenues of US$600M. Prior to his tenure at Merrel, Jim served as President of Red Bull Canada, playing an instrumental role in launching the Red Bull brand in Canada and growing the business to $150 million in annual revenue with over 300 employees nationwide.
“I am very excited to be part of a company that is leading the way in finding alternative solutions to traditional pharmaceuticals with science based research and functional products. My background in heavily regulated industries coupled with my experience in the CPG space provides a great compliment to an already talented and experienced advisory board,” commented Jim Bailey.
Mr. Bailey will champion the marketing, distribution and commercialization of the Company’s Novo Formulations-branded novel delivery systems for the pharmaceutical, nutraceutical and psychedelic medicine industries. Novo Formulations, a 100% owned subsidiary of Champignon, is presently working with ketamine, anaesthetics and adaptogenics, as well as a host of pharmaceuticals and natural molecules at a purpose-built good manufacturing practice (GMP) and pharmaceutical (DIN) licensed facility located in Quebec, Canada. There, the Company is actively formulating, developing and working to commercialize bioavailable delivery platforms, including: Transdermal (topical), intranasal and sublingual.
SHRM Stock Price Action & Chart
Shares of Champignon Brands’ CSE listed SHRM stock climbed 4% to close today’s trading session at $0.78 per share. The company’s American OTC Markets listed SHRMF stock closed the day at $0.55, up 0.3%. Across the Atlantic on the Frankfurt Stock Exchange, Champignon’s German listed shares soared 14.35% to close the session at $0.53 per share.
Champignon Brands is a paid client of The Cannabis Investor. The Cannabis Investor holds a position in Champignon Brands.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.